MedTrace Logo

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

NCT06796998 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-10-28

No results posted yet for this study

Summary

The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).

Conditions

  • Marginal Zone Lymphoma
  • Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
  • Splenic Marginal Zone Lymphoma
  • Nodal Marginal Zone Lymphoma

Interventions

BIOLOGICAL

Epcoritamab

Epcoritamab will be administered via subcutaneous (SC) injection using a step-up dosing schedule as follows: * Cycle 1, Day 1: 0.16 mg * Cycle 1, Day 8: 0.8 mg * Cycle 1, Day 15: 3 mg * Cycle 1, Day 22: 48 mg * Cycles 2 to 3, Days 1, 8, 15 and 22: 48 mg * Cycles 4 to 9, Days 1 and 15: 48 mg * Cycles 10 to 12; Day 1: 48 mg

Sponsors & Collaborators

  • Genmab

    collaborator INDUSTRY

  • AbbVie

    collaborator INDUSTRY

  • Izidore Lossos, MD

    lead OTHER

Principal Investigators

  • Izidore Lossos, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-13
Primary Completion
2028-10-15
Completion
2031-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06796998 on ClinicalTrials.gov